Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression

Fernando Magdaleno^{1

2}, Jonel Trebicka^{1

3

4}

Affiliations

¹ Department of Internal Medicine I, University of Bonn, Bonn, Germany.
² Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
³ Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
⁴ European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, Barcelona, Spain.

Comment

Fernando Magdaleno et al. Gut. 2017 Sep.

. 2017 Sep;66(9):1540-1541.

doi: 10.1136/gutjnl-2016-313621. Epub 2017 Feb 28.

Fernando Magdaleno^{1

2}, Jonel Trebicka^{1

3

4}

¹ Department of Internal Medicine I, University of Bonn, Bonn, Germany.
² Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
³ Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
⁴ European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, Barcelona, Spain.

No abstract available

Keywords: EXTRACELLULAR MATRIX; FIBROSIS; LIVER CIRRHOSIS.

Conflict of interest statement

Competing interests: None declared.

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, Mikels-Vigdal A, Smith V, Schuppan D, Popov YV. Ikenaga N, et al. Gut. 2017 Sep;66(9):1697-1708. doi: 10.1136/gutjnl-2016-312473. Epub 2017 Jan 10. Gut. 2017. PMID: 28073888 Free PMC article.